Hyper Personalized Medicine Market is Expected to Reach $5.9 Trillion by 2031: Allied Market Research

News provided by

Mar 23, 2023, 05:46 ET

PORTLAND, Ore., March 23, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Hyper Personalized Medicine Market by Product (Hyper Personalized Medicine Diagnostics, Hyper Personalized Medicine Therapeutics, Hyper Personalized Medical Care, Hyper Personalized Nutrition and Wellness), by Application (Oncology, Neurology, Blood Transfusion Safety, Diabetes, Autoimmune Diseases, Cardiology), by End User (Hospitals, Diagnostic Centers, Research and Academic Institutes, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global hyper personalized medicine industry was valued at $2.1 trillion in 2021 and is estimated to generate $5.9 Trillion by 2031, witnessing a CAGR of 11.7% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario.

Download Free Sample Report: https://www.alliedmarketresearch.com/request-sample/32349

Drivers, Restraints, and Opportunities

Rising public awareness about hyper personalized medicine, development of efficient and advanced technology, increasing government initiatives around the world, and surging development of genetic databases drive the global hyper personalized medicine market. However, lack of insurance coverage for genetic testing, which is a required test to detect mutations and prescribe personalized medicines, is a major problem, which is restraining the growth of the global hyper personalized medicine market. Moreover, increase in customized medicine usage in neurology, antiviral medicine, pulmonary medicine, and psychiatry, as well as scope in emerging economies will present new growth opportunities for the global market in the coming years.

Covid-19 Scenario:

The COVID-19 pandemic had a mixed impact on the hyper personalized medicine market. The pandemic caused a significant shift in the healthcare business as a whole, with a stronger emphasis on the production and marketing of COVID-19 vaccinations and therapies.
The pandemic caused enormous disruptions in the healthcare industry, including delays in drug trials, supply chain disruptions, and reductions in financing for research and development. These factors hampered the product development and marketing of new hyper personalized medicine.
There was a rise in interest and investment in personalized medicine as a solution to address people's specific healthcare requirements. As a result, a greater emphasis was placed on the creation of tailored therapies and diagnostic technologies. Many governments launched initiatives to accelerate the use of precision medicine in the treatment of coronavirus.

The hyper personalized nutrition and wellness segment to grab the lion's share during the forecast period

Based on product, the hyper personalized nutrition and wellness segment contributed to the largest share of nearly two-fifths of the global hyper personalized medicine market in 2021 and is expected to maintain its dominance during the forecast period. These services offer personalized nutrition and wellness regimens based on an individual's specific needs and preferences, by utilizing data such as genetic information, lifestyle behavior, and health history. On the other hand, the hyper personalized medicine therapeutics segment is projected to witness the fastest CAGR of 12.2% from 2022 to 2031. Hyper-personalized medicine uses advanced technologies such as genomics, proteomics, and artificial intelligence to design targeted treatments that are customized to an individual patient's specific genetic and molecular features.

Procure Complete Report (220 Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.alliedmarketresearch.com/checkout-final/hyper-personalized-medicine-market

The oncology segment to dominate the market during the forecast period

Based on application, the oncology segment grabbed the highest share of more than one-fourth of the hyper personalized medicine market in 2021 and is expected to dominate the market in 2031. Also, the same segment would witness the fastest CAGR of 12.8% from 2022 to 2031. The use of modern technology, including genome sequencing and molecular profiling to discover particular genetic mutations and biomarkers that are propelling the growth of a patient's cancer cells is referred to as hyper-personalized oncology.

The hospitals segment grabbed the highest share in 2021

Based on end user, the hospitals segment accounted for the highest share of more than two-fifths of the global hyper personalized medicine market revenue in 2021 and is expected to maintain its dominance during the forecast period. The same segment would display the highest CAGR of 12.5% from 2022 to 2031. Hospitals play a significant role in the delivery of hyper-personalized medicine, particularly in the administration and monitoring of personalized medicine.

North America to achieve the largest revenue by 2031

Based on region, the market in North America was the largest in 2021, accounting for more than two-fifths of the global hyper personalized medicine market and is expected to rule the roost during the forecast period. The rising healthcare spending, rising patient desire for individualized therapies, and breakthroughs in genomics and other sophisticated technologies are driving innovation in the sector. Asia-Pacific region, on the other hand, is expected to showcase noteworthy CAGR of 12.7% from 2022 to 2031, owing to rising healthcare spending, rising chronic illness prevalence, rising patient demand for tailored therapies, and breakthroughs in genomics and other sophisticated technologies.

Leading Market Players

Abbott,
Dako A/S
Illumina, Inc.
Exact Sciences Corporation
Decode Genetics, Inc.
QIAGEN, Exagen Inc.
GE Healthcare
ASURAGEN, INC.
Danaher Corporation (Cepheid, Inc.)

Trending Reports in Healthcare Industry (Book Now with 10% Discount):

Biosimilars Market by Type (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Granulocyte-Colony Stimulating Factor, Others), by Application (Blood disorders, Oncology diseases, Chronic and autoimmune diseases, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Vaccines Market by Technology Type (Recombinant & Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, and Other Vaccines), Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, & Rubella {MMR}, Diphtheria, Pertussis, & Tetanus {DPT}, Polio, Hepatitis, and Other Indications), and End User (Pediatric, Adults, and Travelers): Global Opportunity Analysis and Industry Forecast, 2021--2031

Telemedicine Market by Application (Teleradiology, Telepsychiatry, Telepathology, Teledermatology, Telecardiology and Other Applications), Component (Software, Hardware and Services), and End User (Healthcare Providers, Payers, Healthcare Consumers and Other End Users): Global Opportunity Analysis and Industry Forecast, 2021-2030

Digital Therapeutics Market by Product (Software and Devices), Sales Channel (Business-to-Business and Business-to-Consumers), Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS), Disease Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID) and Others: Global Opportunity Analysis and Industry Forecast, 2022-2031

Remote Patient Monitoring Market by Condition (Congestive Heart Failure (CHF), Diabetes, Chronic Obstructive Pulmonary Disease (COPD), Blood Pressure, Mental Health, Others), by Component (Devices, Software): Global Opportunity Analysis and Industry Forecast, 2021-2031

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]